Showing results (1091-1100 of 1,632) with videos related to
Sort By:
Pageof 164
Breast Cancer Research and Treatment|January 1, 1993
Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouseD F Gibson, D A Johnson, D Goldstein, et al.Brain Research. Molecular Brain Research|October 1, 1995
Localization of messenger RNAs encoding three GABA transporters in rat brain: an in situ hybridization studyM M Durkin, K E Smith, L A Borden, et al.The Journal of Biological Chemistry|March 27, 2004
Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigenDarran J Wigelsworth, Bryan A Krantz, Kenneth A Christensen, et al.Journal of Chemical Ecology|December 7, 2013
Aggregation pheromones of the flat grain beetle,Cryptolestes pusillus (Coleoptera: Cucujidae)J G Millar, H D Pierce, A M Pierce, et al.Circulation. Cardiovascular Interventions|August 8, 2013
Antianginal therapy before percutaneous coronary interventionWilliam B Borden, John A Spertus, Alvin I Mushlin, et al.Journal of Interferon Research|August 1, 1989
Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gammaD M Paulnock, K A Havlin, B M Storer, et al.Cancer Research|February 1, 1986
Synergistic antiproliferative effects of human recombinant alpha 54- or beta ser-interferon with gamma-interferon on human cell lines of various histogenesisJ H Schiller, D S Groveman, S M Schmid, et al.Molecular Imaging|September 7, 2006
Ultrasound radiation force modulates ligand availability on targeted contrast agentsMark A Borden, Melissa R Sarantos, Susanne M Stieger, et al.Oncotarget|May 10, 2014
Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanomaPowrnima Joshi, Barbara Jacobs, Adeeb Derakhshan, et al.Journal of Interferon Research|June 1, 1988
Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trialE C Borden, M J Hawkins, K M Sielaff, et al.Pageof 164